Your browser does not support java script. Skip navigation
Loading, please wait  Loading, please wait...

New Complementary Combination Therapy for Diabetes: Fixed Dose Basal Insulins and GLP-1 Receptor Agonists


Description:
This activity is designed to educate pharmacists on the role of combination injectable therapy with basal insulin and GLP-1 receptor agonist for patients with diabetes. The activity will include an overview of the ADA and AACE treatment recommendations for patients with type 2 Diabetes.   Participants will understand the pharmacokinetic and pharmacodynamic profiles of currently available basal insulins and GLP-1 agonists.  Data will be presented on the safety and efficacy of basal insulins and GLP-1 agonists administered in combination with a focus on patient selection.  The goal is for pharmacists to counsel patients to improve diabetes self-management and therapeutic outcomes with the use of an emerging fixed combination product.  Case studies will be used to illustrate medication selection, administration, dosing, and adherence management. 
Objectives:
  1. Apply current diabetes guidelines in the management of patients with type 2 diabetes with a specific focus on basal insulin therapy and GLP-1 receptor agonists (GLP-1 RAs)
  2. Compare and contrast the clinical profiles of the different basal insulins and GLP-1 RAs as well as assess their unique PK/PD profiles
  3. Evaluate current data that relate to fixed ratio combinations (GLP-1 RAs and basal insulin)
  4. Describe the clinical rationale and expected benefits of using combination therapy with complementary mechanisms of action
  5. Formulate evidence-based treatment regimens that optimize control of both fasting and postprandial glucose using combination therapy with complementary mechanism of actions
Activity Number:
0280-0000-17-006-H01-P

This recorded activity is a based on a live program that was offered on December 8, 2016 in Randolph, MA.  
Participants who received credit for the live program should not claim credit for this web based presentation.
 
System Requirements for Participants:
Operating system:  Windows XP, Vista or 7  MAC OS X  Latest Version of Adobe Reader
Browser Internet Explorer 8.0 or above  Google Chrome 16.0 or above  Firefox 7.0 or above  Safari 5.0 or above
 

Fee

$0.00

CE Hours

1.25

CE Units

0.125

Activity Type

  • Application Based

Target Audience(s)

  • Pharmacists

Accreditation(s)

Accreditation Council for Pharmacy Education
American Health Resources is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education

Requirements for CE Credit

  • Complete the pre-test
  • Review the content of this activity
  • Successfully complete the post-test with a score of 75% or higher 
  • Complete the evaluation
Continuing pharmacy education credit is automatically reported to CPE Monitor once the post-test & evaluation is completed.
 
Pharmacists - Be sure your profile has been updated with your NAPB e-profile # and birth date information BEFORE completing the online evaluation, or your credits will NOT be reported.

Support/Credits

Disclosures:
The presenter is Dhiren Patel, PharmD, CDE, BC ADM, BCACP; Associate Professor of Pharmacy
Practice, Massachusetts College of Pharmacy and Health Sciences, Boston, MA.   
Dr. Patel is on the speaker’s bureaus of Boehringer Ingelheim, Merck, Novo Nordisk and Sanofi.
Presenter is also an advisory board member and consultant for AstraZeneca, Novo Nordisk, Regeneron and Sanofi. 
 
The reviewer is Regina Ginzburg, PharmD; Associate Clinical Professor, Clinical Health Professions, St. John’s University, NY; Ambulatory Care Clinical Pharmacy Faculty, Mt. Sinai-Beth Israel Family Medicine Residency Program Co-chair, Pharmacy & Therapeutics Committee, Institute for Family Health.
Dr. Ginzburg does not have any relevant financial relationships with any commercial interests   
 
Support for This Activity:
Educational grant funding was received from Novo Nordisk and Sanofi
 
American Health Resources assesses conflict of interest with its instructors, reviewers and other individuals who are in a position to control the content of CE activities. All relevant conflicts of interest that are identified are resolved by American Health Resources for fair balance and scientific objectivity.
 
Disclosure of Unlabeled Use:
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA.  American Health Resources does not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of American Health Resources.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

 

 

 

This activity is designed to educate pharmacists on the role of combination injectable therapy with basal insulin and GLP-1 receptor agonist for patients with diabetes. The activity will include an overview of the ADA and AACE treatment recommendations for patients with type 2 Diabetes.   Participants will understand the pharmacokinetic and pharmacodynamic profiles of currently available basal insulins and GLP-1 agonists.  Data will be presented on the safety and efficacy of basal insulins and GLP-1 agonists administered in combination with a focus on patient selection.  The goal is for pharmacists to counsel patients to improve diabetes self-management and therapeutic outcomes with the use of an emerging fixed combination product.  Case studies will be used to illustrate medication selection, administration, dosing, and adherence management. 

Objectives

  • Apply current diabetes guidelines in the management of patients with type 2 diabetes with a specific focus on basal insulin therapy and GLP-1 receptor agonists (GLP-1 RAs)
  • Compare and contrast the clinical profiles of the different basal insulins and GLP-1 RAs as well as assess their unique PK/PD profiles
  • Evaluate current data that relate to fixed ratio combinations (GLP-1 RAs and basal insulin)
  • Describe the clinical rationale and expected benefits of using combination therapy with complementary mechanisms of action
  • Formulate evidence-based treatment regimens that optimize control of both fasting and postprandial glucose using combination therapy with complementary mechanism of actions

Speaker(s)/Author(s)

Dhiren Patel, PharmD, CDE, BC-ADM, BCACP picture

Dhiren Patel, PharmD, CDE, BC-ADM, BCACP
MCPHS University


Brief Bio : Associate Professor of Pharmacy Practice, Massachusetts College of Pharmacy and Health Sciences University, Boston, MA

Activity Number

0280-0000-17-006-H01-P

Release Date: Jan 12, 2017
Credit Expiration Date: Jan 12, 2019

CE Hours

1.25

Fee

$0.00